We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Basal Bolus Insulin Versus SSRI in Type 2 Diabetes Undergoing General Surgery (RABBIT 2-SX)

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: January 17, 2008
Last Update Posted: March 12, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Guillermo Umpierrez, Emory University

High blood glucose levels in surgical patients with diabetes are associated with increased risk of medical complications and death. Improved glucose control with insulin injections may improve clinical outcome and prevent some of the hospital complications. In patients who have undergone surgery, high blood glucose increases the risk of wound infection, kidney failure and death. It is not known; however, what is the best insulin regimen in patients who will undergo surgery. The use of repeated injections of regular insulin is commonly used for glucose control in hospitalized patients with diabetes. Recently, the combination of Lantus® and Apidra® insulins has been shown to improve glucose control with lower rate of hypoglycemia (low blood sugar). We hypothesize that in patients with type 2 diabetes admitted to general surgery wards, treatment with once daily glargine (Lantus) plus supplemental glulisine insulin (Apidra®) will produce better glycemic control and a lower rate of hospital complications than treatment with regular insulin per sliding scale (SSRI). The present study aims to determine which insulin treatment is best for glucose control in hospitalized patients with diabetes. Glargine and glulisine insulins are approved for use in the treatment of patients with diabetes by the FDA.

Subjects included in the study will have type 2 diabetes and be admitted to Grady Memorial Hospital, Veterans Administration Medical Center, and Emory University Hospital, Atlanta, Georgia. A total of ~94 patients will be recruited at each institution.

A post-hoc cost analysis of hospitalization costs and charges of the Rabbit surgery trial will be completed in order to determine differences in hospitalization cost between basal bolus insulin and SSI regimen.

Condition Intervention Phase
Type 2 Diabetes Inpatient Hyperglycemia Drug: Insulin glargine Drug: Regular insulin Drug: Insulin glulisine Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: RAndomized Study of Basal Bolus Insulin Therapy in the Inpatient Management of Patients With Type 2 Diabetes Undergoing General Surgery (RABBIT 2 Surgery)

Resource links provided by NLM:

Further study details as provided by Guillermo Umpierrez, Emory University:

Primary Outcome Measures:
  • Mean Blood Glucose Concentration [ Time Frame: hospital stay days 2-10 ]
    blood glucose concentration in the intervention groups after second day of treatment to up to 10 days of treatment

Secondary Outcome Measures:
  • # Participants With Hypoglycemic Events [ Time Frame: hospital stay days 2-10 ]
    number of participants in the treatment arms with of hypoglycemic events (< 70 mg/dl)

Enrollment: 234
Study Start Date: December 2007
Study Completion Date: July 2013
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Glargine once daily plus glulisine given before meals plus supplemental glulisine for BG > 140
Drug: Insulin glargine
Insulin glargine once daily SQ
Other Name: Lantus
Drug: Insulin glulisine
scheduled glulisine given SQ at mealtime TID; none given if patient NPO
Other Name: Apidra
Active Comparator: 2
Sliding scale regular insulin four-times daily achs.
Drug: Regular insulin
Sliding scale regular insulin SQ four-times daily before meals or every 6 hours if patient NPO
Other Name: Novolin R


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Males or females between the ages of 18 and 80 years admitted to a general surgery service.
  2. Patients admitted for non-cardiac elective or emergency surgery or trauma.
  3. A known history of type 2 diabetes mellitus > 3 months, receiving either diet alone or any combination of oral antidiabetic agents (sulfonylureas, metformin, thiazolidinediones).
  4. Subjects must have an admission blood glucose > 140 mg and < 400 mg/dL without laboratory evidence of diabetic ketoacidosis (serum bicarbonate < 18 mEq/L or positive serum or urinary ketones).

Exclusion Criteria:

  1. Subjects with increased blood glucose concentration, but without a known history of diabetes (stress hyperglycemia).
  2. Subjects with a history of diabetic ketoacidosis and hyperosmolar hyperglycemic state, or ketonuria.
  3. Acute critical illness or CABG surgery expected to require prolonged admission to a critical care unit (ICU, CCU, SICU, Neuro ICU).
  4. Patients with clinically relevant hepatic disease or impaired renal function, as shown by a serum creatinine ≥ 3.5 mg/dl.
  5. Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.
  6. Female subjects are pregnant or breast feeding at time of enrollment into the study.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00596687

United States, Georgia
Grady Memorial Hospital
Atlanta, Georgia, United States, 30303
Emory University Hospital
Atlanta, Georgia, United States, 30324
Sponsors and Collaborators
Emory University
Principal Investigator: Guillermo Umpierrez, MD Emory University SOM
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Guillermo Umpierrez, Professor of Medicine, Emory University
ClinicalTrials.gov Identifier: NCT00596687     History of Changes
Other Study ID Numbers: IRB00005062
First Submitted: January 8, 2008
First Posted: January 17, 2008
Results First Submitted: July 9, 2013
Results First Posted: March 12, 2014
Last Update Posted: March 12, 2014
Last Verified: February 2014

Keywords provided by Guillermo Umpierrez, Emory University:
post-op complications
inpatient hyperglycemia

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin, Globin Zinc
Insulin glulisine
Insulin Glargine
Hypoglycemic Agents
Physiological Effects of Drugs